Aptevo Therapeutics Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 18/100
What the filing says
Aptevo Therapeutics issued common stock purchase warrants (exercise price $4.03, 5-year term) and pre-funded warrants ($0.0001 exercise price) to unspecified purchasers on August 12–13, 2026, conditioned on stockholder approval. New Warrant Shares = 500% of Existing Warrant Shares exercised. Company capitalization: 1,555,293 shares outstanding pre-transaction. Specific share counts and dollar amounts not disclosed in filing.
Why this rating
Warrant issuance dilutes shareholders significantly, but small company ($9.8M) and routine warrant offering structure. Negative on shareholder approval condition and 500% warrant multiplier creating downstream dilution.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.